Considering that the levels of SHARPIN and STING proteins were the highest regulated with the delphinidin treatments at concentrations of 120 μM for 24 h, we performed a bioinformatic analysis using the GlioVis platform to evaluate the survival of patients, concerning the expression levels of both markers in glioblastoma and their possible correlation with MGMT expression. The gene discussed is MGMT; the disease is glioblastoma.